| Literature DB >> 36245484 |
Lin Chen1, Bosen Hu1, Xiaohong Wang1, Yong Chen2, Bo Zhou1.
Abstract
Cyanidin-3-O-glucoside (C3G) is the most widely distributed anthocyanin and it can reportedly reduce the risk of osteoporosis, but the molecular mechanism by which C3G promotes bone formation is poorly understood. In the current study, RNA sequencing (RNA-seq) was used to investigate the mechanism of action of C3G in osteogenesis. MC3T3-E1 mouse osteoblasts were divided into a C3G (100 μmol/L)-treated group and a vehicle-treated control group, and differentially expressed genes (DEGs) in groups were evaluated via RNA-seq analysis. The functions of the DEGs were evaluated by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, and the genes were validated by quantitative real-time PCR. The RNA-seq analysis identified 34 genes that were upregulated in C3G-treated cells compared to vehicle-treated cells, and 17 that were downregulated GO and KEGG pathway analyses indicated that these genes were highly enriched in functions related to lysosomes and glycolipid biosynthesis, among others. The differential expression of ATPase H+-transporting V0 subunit C (Atp6v0c), chemokine (C-X3-C motif) ligand 1 (Cx3cl1), and lymphocyte antigen 6 complex, locus A (Ly6a) genes was validated by quantitative real-time-PCR. Because these genes have been previously implicated in osteoporosis, they are potential target genes of C3G action in MC3T3-E1 cells. These results provide molecular level evidence for the therapeutic potential of C3G in the treatment of osteoporosis and other disorders of bone metabolism.Entities:
Keywords: Atp6v0c; Cx3cl1; Ly6a; MC3T3-E1 cells; RNA-sequencing; cyanidin-3-O-glucoside; osteogenesis
Year: 2022 PMID: 36245484 PMCID: PMC9562617 DOI: 10.3389/fnut.2022.995643
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
Primer sequences used in the study.
|
|
|
|
|
|---|---|---|---|
| LSM12-f | CAGCGTTCACAAGCCCAACAAC | Cx3cl1-f | CTACTAGGAGCTGCGACACG |
| LSM12-r | CACTGAAGCCACCACCACCATC | Cx3cl1-r | TGTCGTCTCCAGGACAATGG |
| Foxp1-f | CAAGCTGTGCACCCCATACA | Adprhl2-f | TGAGCCGAGAGGAAGTGGTGTC |
| Foxp1-r | TGTACAAGAAACGGAGGGCG | Adprhl2-r | GCAGCGCAGGAAGCAGTAGATG |
| Ly6a-f | CCTGCTGGGTAGGTAGGTGCTC | Txndc5-f | GCCGCTGCTCGTAACTCTGTG |
| Ly6a-r | CCTCTTCACTGTGCTGGCTGTG | Txndc5-r | CCGCTCGTGGGAGGTAGGTG |
| Cenpx-f | CGGAAGGAACTGGTGAGCAGAC | Ppp1r15a-f | AGCATGGGCACGCCTTAGAAAC |
| Cenpx-r | ACGGACAGCAGCCTCTAGTACG | Ppp1r15a-r | CCGCCTCCCTCCCAAGTACAG |
| Defb25-f | ATGCACCTGTGTCCGGATG | Tmem55b-f | CGTACGGAGCCGGTAAACA |
| Defb25-r | ATGGCATCAACTCTAGAGCAA | Tmem55b-r | TCTTGATGGGAGTGGCTTCG |
| Pigc-f | AGTAGTCCCCTTCCAAGCCG | Camk2g-f | CCGCCCGAGATCATCAGAAA |
| Pigc-r | GCTAAATTCCTGCACCAAGCTC | Camk2g-r | CTTGACACCGCCATCTGACT |
| Atp6v0c-f | ACGAACAGCCTGACACATGCAC | Gm20521-f | CTCTAGCCGGGAGGATGAAAG |
| Atp6v0c-r | GCCTGGGTGGGAGATGAGTGG | Gm20521-r | CCAACGTAGATAGAGCGGGC |
| Ccdc115-f | GGTGGAGGAGGGTTGGCTCTC | Nkiras2-F | CGGGAGCAGGTGCGTTTCTATG |
| Ccdc115-r | GCACGCACGCAGACCTGAG | Nkiras2-R | ACGTAGCCATCGGTGCAGGAG |
| Ugt1a7c-f | TTGCCTTAGGCTGCACTTCT | Tex2-f | GAGTGGTTCAGGCGGTTCATCC |
| Ugt1a7c-r | TCCGGAACAACCACTACGAC | Tex2-r | GCTGCTGCTGCGGCTGTG |
| Nfya-f | CAGCCGTTAATGGTGCAAGT | Iqcd-f | GCGAGAAGCAGGACGAATAC |
| Nfya-r | GAGGCACCAACTGTATCTGCT | Iqcd-f | CCACCCGCTTCTTGGAATTG |
| GAPDH-f | TTGTCTCCTGCGACTTCAACA | ||
| GAPDH-r | GTGGTCCCAGGGTTTCTTACTCC |
Figure 1Heatmaps and volcano plot of DEGs in C3G-treated vs. untreated control MC3T3-E1 cells. (A) Heatmap of 34 upregulated and 17 downregulated DEGs. (B) Volcano plot of upregulated (red dots) and downregulated (green dots) DEGs and genes expressed at a normal level (gray dots).
Top 10 enriched BP terms of up-regulated and down-regulated DEGs.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
| |||||
| GO:0007042 | Lysosomal lumen acidification | Atp6v0c, Ccdc115 | 0.000051713 | 0.031235009 | 4.286395308 |
| GO:0035751 | Regulation of lysosomal lumen pH | Atp6v0c, Ccdc115 | 0.000121475 | 0.036685321 | 3.915514623 |
| GO:0007035 | Vacuolar acidification | Atp6v0c, Ccdc115 | 0.000280141 | 0.056401623 | 3.552624083 |
| GO:0042157 | Lipoprotein metabolic process | Lyplal1, Pigc, Pigk | 0.000496347 | 0.060730184 | 3.30421487 |
| GO:0034508 | Centromere complex assembly | Cenpx, Hjurp | 0.000502733 | 0.060730184 | 3.298662336 |
| GO:0051452 | Intracellular pH reduction | Atp6v0c, Ccdc115 | 0.000686147 | 0.064043499 | 3.163582969 |
| GO:0006506 | GPI anchor biosynthetic process | Pigc, Pigk | 0.000841882 | 0.064043499 | 3.074749022 |
| GO:0045851 | pH reduction | Atp6v0c, Ccdc115 | 0.00089723 | 0.064043499 | 3.047095975 |
| GO:0006505 | GPI anchor metabolic process | Pigc, Pigk | 0.000954291 | 0.064043499 | 3.020319376 |
| GO:0009247 | Glycolipid biosynthetic process | Pigc, Pigk | 0.002633397 | 0.083516259 | 2.579483631 |
|
| |||||
| GO:0033554 | Cellular response to stress | Adprhl2, Faap24, Gm20521, Ppp1r15a, Rad1 | 0.001529696 | 0.114686788 | 2.815395 |
| GO:0006950 | Response to stress | Adprhl2, Camk2g, Cx3cl1, Faap24, Gm20521, Ppp1r15a, Rad1 | 0.002156548 | 0.114686788 | 2.66624084 |
| GO:0033135 | Regulation of peptidyl-serine phosphorylation | Ppp1r15a, Smad7 | 0.004392513 | 0.114686788 | 2.357286896 |
| GO:0045216 | cell-cell junction organization | Nectin1, Smad7 | 0.004863323 | 0.114686788 | 2.313066923 |
| GO:0051179 | localization | Camk2g, Cx3cl1, Nectin1, Ppp1r15a, Smad7, Tex2, Txndc5, Ubl4a | 0.006595983 | 0.114686788 | 2.180720442 |
| GO:0006974 | Cellular response to DNA damage stimulus | Faap24, Gm20521, Rad1 | 0.008369015 | 0.114686788 | 2.077325642 |
| GO:0090257 | Regulation of muscle system process | Camk2g, Smad7 | 0.009416313 | 0.114686788 | 2.026119096 |
| GO:2001234 | Negative regulation of apoptotic signaling pathway | Cx3cl1, Gm20521 | 0.009662976 | 0.114686788 | 2.014889099 |
| GO:0022409 | Positive regulation of cell-cell adhesion | Cx3cl1, Smad7 | 0.009996352 | 0.114686788 | 2.000158469 |
| GO:0001818 | Negative regulation of cytokine production | Cx3cl1, Smad7 | 0.010420254 | 0.114686788 | 1.982121684 |
Figure 2GO analysis of DEGs in C3G-treated MC3T3-E1 cells and untreated control MC3T3-E1 cells. Enriched GO terms corresponding to DEGs in the biological process (BP), cellular component (CC), and molecular function (MF) categories are shown. (A–D) GO terms based on upregulated (A,B) and downregulated (C,D) DEGs.
Signaling pathway enrichment of up-regulated and down-regulated DEGs.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
| |||||
| mmu00563 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | Pigc, Pigk | 0.000600808 | 0.019225871 | 3.221263961 |
| mmu05152 | Tuberculosis | Atp6v0c, Fcgr4, Nfya | 0.002024514 | 0.032392223 | 2.693679229 |
| mmu05322 | Systemic lupus erythematosus | Fcgr4, Hist1h2bq | 0.018196375 | 0.173813623 | 1.740015125 |
| mmu04145 | Phagosome | Atp6v0c, Fcgr4 | 0.028375513 | 0.173813623 | 1.547056275 |
|
| |||||
| mmu04141 | Protein processing in endoplasmic reticulum | Ppp1r15a, Txndc5 | 0.000600808 | 0.199802063 | 1.961455096 |
Figure 3Enriched KEGG pathways of upregulated DEGs and downregulated DEGs. (A,B) Dot plots showing the enrichment score (–log10[p-value]) of significantly enriched pathways (A) and the gene ratio of the top 10 most significantly enriched pathways (B). (C) Bar plot showing the top 10 enrichment scores (–log10[p-value]) of significantly enriched pathways. (D,E) Dot plots showing the enrichment score (–log10[p-value]) of the significantly enriched pathways (D) and the gene ratios of the top 10 most significantly enriched pathways (E). (F) Bar plot showing the top 10 enrichment scores (–log10[p-value]) of significantly enriched pathways.
Figure 4qRT-PCR validation of top DEGs. (A,B) Expression levels of top 10 upregulated (A) and downregulated (B) DEGs evaluated by qRT-PCR (n = 3 replicates). *p < 0.05, **p < 0.01.